CAS:1310726-60-3 | Upadacitinib

Introduction and application of CAS 1310726-60-3 | Upadacitinib

Inhibitor of Janus kinase JAK-1

Scientific research reagents are widely used in molecular biology, pharmacology and other scientific research, and are strictly prohibited from use on the human body. Upadacitinib (ABT-494) is a highly effective and selective JAK1 inhibitor used in the treatment of some autoimmune diseases and research in related fields.

Synonyms:

(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide;

ABT 494;

Upadacitinib;

1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-;

rel-(-)-(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;

Specification of CAS 1310726-60-3 | Upadacitinib

Package and transportation of Introduction and application of CAS 1310726-60-3 | Upadacitinib

Package:0.1g,1g,5g,25g,100g,500g,1kg

Transportation: by courier/ by air/ by sea

Related Articles of CAS 1310726-60-3 | Upadacitinib

Upadacitinib for the treatment of rheumatoid arthritis

L Serhal, CJ Edwards - Expert Review of Clinical Immunology, 2019 - Taylor & Francis

… upadacitinib extended-release 15 and 30 mg daily selected in phase III RA studies have shown

a near-maximum efficacy in phase II studies. Upadacitinib … ), upadacitinib was superior to …

Hot Tags: cas:1310726-60-3 | upadacitinib, China cas:1310726-60-3 | upadacitinib manufacturers, factory, 4 Amino 4H 1 2 4 triazole, 2-Bromo-m-xylene, Cordycepin, 3 deoxy adenosin, Methyl toluenesulfonate, Pharmaceutical Intermediates